---
title: "Immuneering (IMRX) Gets a Buy from Chardan Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286964427.md"
description: "Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Immuneering (IMRX) with a price target of $20.00. Livshits, who focuses on the Healthcare sector, has an average return of 7.8% and a 35.98% success rate on recommended stocks. Mizuho Securities also maintained a Buy rating on the stock, setting a price target of $12.00."
datetime: "2026-05-19T20:35:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286964427.md)
  - [en](https://longbridge.com/en/news/286964427.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286964427.md)
---

# Immuneering (IMRX) Gets a Buy from Chardan Capital

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immuneering today and set a price target of $20.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Iovance Biotherapeutics, and Tenaya Therapeutics. According to TipRanks, Livshits has an average return of 7.8% and a 35.98% success rate on recommended stocks.

In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $12.00 price target.

### Related Stocks

- [IMRX.US](https://longbridge.com/en/quote/IMRX.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)
- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)
- [TNYA.US](https://longbridge.com/en/quote/TNYA.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)